PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results

19055 Background: Anti-angiogenesis is the new paradigm in the management of non-small cell lung cancer. Platelet Derived Growth Factor Receptor alpha (PDGFR-alpha) is involved in angiogenesis and its expression has been found in lung cancer. Preclinical models have shown that I inhibit PDGFR and may subsequently inhibit angiogenesis. Second line D monotherapy for NSCLC produces a response rate of 8- 10% and a median survival of 6–8 months. Weekly D had similar efficacy compared with every 3 week schedule with better tolerability. In addition, I + D have additive anticancer activity. We initiated a phase II trial of I +D to evaluate the efficacy and safety of this regimen in recurrent NSCLC. The primary endpoint was response rate using Simon two-stage design. A total of 32 patients is planned. Methods: Patients (pts)with pathologically confirmed NSCLC, measurable disease, no more than 1 previous platinum-based chemotherapy regimen, PS 0–1, clinically stable brain metastases and adequate organ function wer...